NeoGenomics Reports Second Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Fiserv president resigns, interim leaders named for financial unit
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Needham Reiterates Buy Rating on Neogenomics (NEO)
July 30, 2024 6:04 AM EDTNeedham analyst Mike Matson reiterated a Buy rating and $19.00 price target on Neogenomics (NASDAQ: NEO).
The analyst comments "NEO's 2Q24 revenue and EBITDA beat consensus and management raised 2024 revenue and EBITDA guidance. Revenue growth slowed to 12% Y/Y in 2Q24 from 14% in 1Q24,... More
